Featured Research

from universities, journals, and other organizations

First dual-protection intravaginal ring design shows promise in long-term HIV, pregnancy prevention

Date:
November 12, 2013
Source:
American Association of Pharmaceutical Scientists
Summary:
A new intravaginal ring has been developed for the sustained 90-day co-delivery of tenofovir and levonorgestrel, an anti-human immunodeficiency virus (HIV) drug and a contraceptive. Tenofovir is the only topical prophylactic shown to be effective at reducing the sexual transmission of HIV when formulated in a gel.

A new intravaginal ring (IVR) has been developed for the sustained 90-day co-delivery of tenofovir and levonorgestrel, an anti-human immunodeficiency virus (HIV) drug and a contraceptive. Tenofovir is the only topical prophylactic shown to be effective at reducing the sexual transmission of HIV when formulated in a gel. This research is being presented at the 2013 American Association of Pharmaceutical Scientists (AAPS) Annual Meeting and Exposition, the world's largest pharmaceutical sciences meeting, in San Antonio, Nov. 10-14.

Related Articles


While there are 35.3 million people living with HIV around the world, approximately 87 million unintended pregnancies occur each year, according to the World Health Organization. Meredith Clark, Ph.D., and David Friend, Ph.D., from CONRAD, a reproductive health research organization, in collaboration with the University of Utah, created this IVR using a dual-protection or multipurpose prevention technology (MPT) to concurrently protect women from the sexual transmission of HIV and unintended pregnancy.

They designed the ring using reservoir-type polyurethane segments that were individually optimized to deliver each drug at the desired dosage -- a high flux of tenofovir and low flux of levonorgestrel. The researchers performed in-vitro release testing, and 3-month pharmacokinetic (PK) studies in rabbits and sheep were done in comparison against the tenofovir gel.

The PK studies found that local levels of tenofovir in the target tissue delivered from the IVR are similar or higher than the levels following gel application. In addition, release of the contraceptive agent was consistent with previous levels tested to be efficacious in women.

"We saw the urgent need to make this dual-protection intravaginal ring because a majority of the world's unintended pregnancies occur within resource-poor regions where the HIV/AIDS pandemic is most prevalent, such as sub-Saharan Africa," said Clark. "MPTs are a relatively new reproductive health technology that we expect will have a good deal of support from potential users, donors, and public health organizations, particularly in the developing world. We anticipate a lot of excitement for this product, as it is the first dual-protection ring to be evaluated clinically."

A team of investigators led by Patrick Kiser, now at Northwestern University, in partnership with CONRAD, presented research at the 2012 AAPS Annual Meeting on an intravaginal ring to deliver solely tenofovir. (Click here to view this release from last year's Annual Meeting.)

CONRAD's Product Development group and collaborators are continuing stability studies now and anticipate beginning with phase 1 clinical trials in women in early 2014, testing the combination anti-HIV/contraceptive IVR versus the anti-HIV-only IVR.


Story Source:

The above story is based on materials provided by American Association of Pharmaceutical Scientists. Note: Materials may be edited for content and length.


Cite This Page:

American Association of Pharmaceutical Scientists. "First dual-protection intravaginal ring design shows promise in long-term HIV, pregnancy prevention." ScienceDaily. ScienceDaily, 12 November 2013. <www.sciencedaily.com/releases/2013/11/131112105022.htm>.
American Association of Pharmaceutical Scientists. (2013, November 12). First dual-protection intravaginal ring design shows promise in long-term HIV, pregnancy prevention. ScienceDaily. Retrieved March 29, 2015 from www.sciencedaily.com/releases/2013/11/131112105022.htm
American Association of Pharmaceutical Scientists. "First dual-protection intravaginal ring design shows promise in long-term HIV, pregnancy prevention." ScienceDaily. www.sciencedaily.com/releases/2013/11/131112105022.htm (accessed March 29, 2015).

Share This


More From ScienceDaily



More Health & Medicine News

Sunday, March 29, 2015

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

S. Leone in New Anti-Ebola Lockdown

S. Leone in New Anti-Ebola Lockdown

AFP (Mar. 28, 2015) Sierra Leone imposed a three-day nationwide lockdown Friday for the second time in six months in a bid to prevent a resurgence of the deadly Ebola virus. Duration: 01:17 Video provided by AFP
Powered by NewsLook.com
These Popular Antibiotics Can Cause Permanent Nerve Damage

These Popular Antibiotics Can Cause Permanent Nerve Damage

Newsy (Mar. 27, 2015) A popular class of antibiotic can leave patients in severe pain and even result in permanent nerve damage. Video provided by Newsy
Powered by NewsLook.com
WH Plan to Fight Antibiotic-Resistant Germs

WH Plan to Fight Antibiotic-Resistant Germs

AP (Mar. 27, 2015) The White House on Friday announced a five-year plan to fight the threat posed by antibiotic-resistant bacteria amid fears that once-treatable germs could become deadly. (March 27) Video provided by AP
Powered by NewsLook.com
House Ready to Pass Medicare Doc Bill

House Ready to Pass Medicare Doc Bill

AP (Mar. 26, 2015) In rare bipartisan harmony, congressional leaders pushed a $214 billion bill permanently blocking physician Medicare cuts toward House passage Thursday, moving lawmakers closer to resolving a problem that has plagued them for years. (March 26) Video provided by AP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:

Strange & Offbeat Stories


Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins